Plus Therapeutics

07/29/2025

’ ongoing ReSPECT-LM dose-optimization for in patients with (LM) aims to refine treatment regimens for the challenging central nervous system ( ) complication.

Check out Sabrina Serani’s recent article in Targeted Oncology, which covers the trial and includes a quote from ’s President and CEO, Marc Hedrick, M.D.

Full article linked here: bit.ly/4ocOJeS

Learn more about the clinical trial here: bit.ly/45OBc6O

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

07/25/2025

From catheter-based delivery to patient-informed trial design, Plus Therapeutics is reshaping neuro-oncology with targeted radiotherapeutics. Catch our latest conversation with Plus Therapeutics’ CEO Dr. Marc Hedrick in this Xtalks Clinical Edge™ feature at https://buff.ly/pRaIpox by Soumya Shashikumar.

07/23/2025

announces that the Company received notice of an advance payment of $1.6 million from the Cancer Prevention and Research Institute of Texas (), the second-largest public cancer research funder globally, as part of the Company’s previously awarded $17.6 million grant. This payment is part of $17.6 million award granted for .

Read the full press release here: bit.ly/4kS0SDa

07/22/2025

Today is , a moment created by the World Federation of Neurology - WFN to raise awareness about and neurological disorders.

One of our Principal Investigators for our RESPECT-GBM trial, Andrew Brenner, M.D., Ph.D., recently spoke to about how and vaccines are providing potential breakthroughs in ( ) care. Dr. Brenner also discusses the positive results from our phase 1/2 ReSPECT-GBM trial (NCT01906385) that evaluated rhenium obisbemeda in patients with recurrent glioma.

Check out the video here: https://bit.ly/3II4hah

Our team is continuing to actively recruit patients for the ongoing RESPECT-GBM Phase 2 . Please visit the website if you or someone you know may be eligible: respect-trails.com/gbm or email us at respect@plustherapeutics.com.



Thegameongliopodcast, National Brain Tumor Society, American Brain Tumor Association, End Brain Cancer Initiative - the Chris Elliott Fund, Glioblastoma Research Organization, Say YES to HOPE, Brain Tumor Network, Head For The Cure

“Dendritic cell vaccines, CAR T-cell therapy, and things of that nature are holding some promise,” said Andrew Brenner, MD, PhD.

07/21/2025

Central nervous system ( ) cancers such as including ( ) and , remain among the most difficult to treat and have limited U.S. Food and Drug Administration-approved options.

In a recent Clinical Edge interview, ' President and CEO, Marc Hedrick, discusses how our team is addressing this unmet need with targeted designed for precision delivery in the brain and spinal cord.

Read the full interview to learn more about this bold approach to innovation here:

Dr. Marc Hedrick, President and CEO of Plus Therapeutics, discusses how the company is exploring targeted radiotherapeutics for CNS cancers.

07/16/2025

As we continue to highlight , we’re sharing another clip from the video interview given by one of our Principal Investigators in the RESPECT-GBM trial, Andrew Brenner, M.D., Ph.D.

Dr. Brenner discusses how recurrent ( ) patients who had an absorbed dose of greater than 100 Gy with our , REYOBIQ™ (rhenium Re186 obisbemeda), had a median overall survival of 17 months.

Check out the video here: https://www.cancernetwork.com/view/rhenium-obisbemeda-shows-no-dlts-and-improves-survival-in-recurrent-glioma

Our team is continuing to actively recruit patients for the ongoing RESPECT-GBM Phase 2 . Please visit the website if you or someone you know may be eligible: respect-trials.com/gbm or email us at respect@plustherapeutics.com.



Thegameongliopodcast, National Brain Tumor Society, American Brain Tumor Association, End Brain Cancer Initiative - the Chris Elliott Fund, Glioblastoma Research Organization, Say YES to HOPE, Brain Tumor Network, Head For The Cure

According to Andrew Brenner, MD, PhD, rhenium obisbemeda can be detected via SPECT imaging and aids in the care of patients with glioblastoma.

07/16/2025

Today is , a key moment to spread awareness of ( ) and the vital work being done to support the unmet need for patients with this cancer across the globe.

One of our Principal Investigators for our RESPECT-GBM trial, Andrew Brenner, M.D., Ph.D., recently spoke to about how our investigational therapy, REYOBIQ™ (rhenium Re186 obisbemeda), can be detected via SPECT imaging and aids in the care of patients with GBM.

Check out the video here: https://www.cancernetwork.com/view/rhenium-obisbemeda-maintains-and-distributes-radioisotopes-in-glioma

Our team is continuing to actively recruit patients for the ongoing RESPECT-GBM Phase 2 . Please visit the website if you or someone you know may be eligible: respect-trials.com/gbm or email us at respect@plustherapeutics.com.



Thegameongliopodcast, National Brain Tumor Society, American Brain Tumor Association, End Brain Cancer Initiative - the Chris Elliott Fund, Glioblastoma Research Organization, Say YES to HOPE, Brain Tumor Network, Head For The Cure

According to Andrew Brenner, MD, PhD, rhenium obisbemeda can be detected via SPECT imaging and aids in the care of patients with glioblastoma.

07/15/2025

announces the oral presentation of its ReSPECT-LM results and a sponsored educational symposium, at the upcoming / Metastases Conference on August 14-16, 2025, at the Baltimore Waterfront Marriott Hotel in Baltimore, MD.

Learn more about each presentation in our press release: https://bit.ly/453bSZQ

American Society of Clinical Oncology

07/10/2025

announces that CNSide Diagnostics ( ) will be showcasing two presentations at the upcoming / Metastases Conference on August 14-16, 2025, in Baltimore, MD.

Read the full press release for details on both presentations: https://bit.ly/4nAWWt7

American Society of Clinical Oncology

07/08/2025

announces the treatment of its initial patients in the Company’s ReSPECT-LM dose optimization trial for REYOBIQ™ (rhenium Re 186 obisbemeda) for the treatment of (LM).

This builds on promising results from ’s completed Phase 1 single-dose escalation study, which demonstrated the feasibility of REYOBIQ for treating LM. The trial is designed in alignment with the U.S. Food and Drug Administration’s to identify the optimal dosing regimen that maximizes efficacy and safety. The substantial clinical need is expected to facilitate rapid overall trial enrollment.

Read the full press release here: https://bit.ly/4nIlPDw

Learn more about the ReSPECT-LM trial here: https://bit.ly/45OBc6O

UT Health San Antonio

06/30/2025

announces the initiation of the ReSPECT-LM dose optimization trial for ™ (rhenium Re 186 obisbemeda) for the treatment of (LM).

The ’s primary objective is to determine optimal dosing schedule for a registrational trial and it will build on recommended Phase 2 dose determined in the completed Phase 1. ReSPECT-LM benefits from $17.6M award from CPRIT.

Read the full press release here: bit.ly/4ls3AzX

ReSPECT-LM website: bit.ly/45OBc6O

06/26/2025

announces a business update for its wholly-owned subsidiary, CNSide Diagnostics, LLC. The proprietary CNSide Cerebrospinal Fluid (CSF) Assay Platform is designed and intended for patients suspected of having cancer metastases (CNS Mets).

The U.S. commercial rollout of its novel diagnostic platform is expected to begin in the second half of 2025.

CNSide is targeting the underserved U.S. CNS cancer diagnostic market, which represents an opportunity estimated to be in excess of $6 billion.

Management will host a conference call today at 9:00 a.m. ET to discuss and provide additional details.

Read the full press release here: bit.ly/4elBZhN

Join the webcast here: bit.ly/3TJXz5S